S

SoftOx Solutions AS
OSE:SOFTX

Watchlist Manager
SoftOx Solutions AS
OSE:SOFTX
Watchlist
Price: 0.0776 NOK -0.77% Market Closed
Market Cap: 173.9m NOK

Relative Value

The Relative Value of one SOFTX stock under the Base Case scenario is 0.0566 NOK. Compared to the current market price of 0.0776 NOK, SoftOx Solutions AS is Overvalued by 27%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SOFTX Relative Value
Base Case
0.0566 NOK
Overvaluation 27%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
84
vs Industry
19
Median 3Y
698.5
Median 5Y
8 566.6
Industry
2.5
vs History
vs Industry
Median 3Y
-271
Median 5Y
-856.6
Industry
21.5
vs History
7
vs Industry
42
Median 3Y
-219.8
Median 5Y
-812.1
Industry
16.6
vs History
3
vs Industry
26
Median 3Y
-257.8
Median 5Y
-842.1
Industry
24.9
vs History
79
vs Industry
58
Median 3Y
400.9
Median 5Y
1 157.2
Industry
2.1
vs History
84
vs Industry
19
Median 3Y
697.6
Median 5Y
8 565.6
Industry
2.7
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.2
vs History
vs Industry
54
Median 3Y
-223.2
Median 5Y
-699.1
Industry
12.8
vs History
vs Industry
51
Median 3Y
-210.3
Median 5Y
-669.2
Industry
16.3
vs History
7
vs Industry
43
Median 3Y
-219.7
Median 5Y
-812.3
Industry
14.9
vs History
3
vs Industry
27
Median 3Y
-257.5
Median 5Y
-842.2
Industry
17.9
vs History
84
vs Industry
52
Median 3Y
126.3
Median 5Y
969.9
Industry
1.9

Multiples Across Competitors

SOFTX Competitors Multiples
SoftOx Solutions AS Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
SoftOx Solutions AS
OSE:SOFTX
173.9m NOK 13.1 -2 -3 -2.7
US
Eli Lilly and Co
NYSE:LLY
766.3B USD 15.6 69 37 40.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK 7.6 21.9 15.1 17.4
CH
Roche Holding AG
SIX:ROG
214.7B CHF 3.5 25.9 9.7 11.4
CH
Novartis AG
SIX:NOVN
190B CHF 4.4 18.1 10.6 14.2
UK
AstraZeneca PLC
LSE:AZN
169.1B GBP 4.2 29.5 131.3 198
US
Merck & Co Inc
NYSE:MRK
202.1B USD 3.2 11.6 8.6 10.5
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
139.2B USD 2.2 17.7 7.6 10.6
P/E Multiple
Earnings Growth PEG
NO
S
SoftOx Solutions AS
OSE:SOFTX
Average P/E: 26.4
Negative Multiple: -2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
69
50%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
21.9
18%
1.2
CH
Roche Holding AG
SIX:ROG
25.9
32%
0.8
CH
Novartis AG
SIX:NOVN
18.1
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
29.5
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.6
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.7
31%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
S
SoftOx Solutions AS
OSE:SOFTX
Average EV/EBITDA: 434
Negative Multiple: -3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
15.1
13%
1.2
CH
Roche Holding AG
SIX:ROG
9.7
5%
1.9
CH
Novartis AG
SIX:NOVN
10.6
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131.3
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.6
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
2%
3.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
S
SoftOx Solutions AS
OSE:SOFTX
Average EV/EBIT: 1 867.7
Negative Multiple: -2.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.4
32%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
17.4
14%
1.2
CH
Roche Holding AG
SIX:ROG
11.4
6%
1.9
CH
Novartis AG
SIX:NOVN
14.2
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
198
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.5
11%
1
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.6
10%
1.1